FI105202B - Förfarande för framställning av aktiverbara fibrinolytiska och antikombotiska plasminogenanaloga - Google Patents

Förfarande för framställning av aktiverbara fibrinolytiska och antikombotiska plasminogenanaloga Download PDF

Info

Publication number
FI105202B
FI105202B FI922610A FI922610A FI105202B FI 105202 B FI105202 B FI 105202B FI 922610 A FI922610 A FI 922610A FI 922610 A FI922610 A FI 922610A FI 105202 B FI105202 B FI 105202B
Authority
FI
Finland
Prior art keywords
plasminogen
factor
thrombin
protein
arg
Prior art date
Application number
FI922610A
Other languages
English (en)
Finnish (fi)
Other versions
FI922610A (fi
FI922610A0 (fi
Inventor
Keith Martyn Dawson
Richard Mark Edwards
Joan Mabel Forman
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of FI922610A publication Critical patent/FI922610A/fi
Publication of FI922610A0 publication Critical patent/FI922610A0/fi
Application granted granted Critical
Publication of FI105202B publication Critical patent/FI105202B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C12N2830/704—S. cerevisiae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/107—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translational read-through

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (6)

1. Förfarande för framställning av en plasminogenanalog som kan aktiveras med blodkoaguleringsenzym för att fa plasminaktivitet, kännetecknat av att värdcellen transfekteras eller transformeras med en expressionsvektor innehallande en DNA-5 sekvens som kodar nämnda plasminogenanalog, cellen odlas pä ett lämpligt växt-substrat under forhällanden som möjliggör expression av plasminogenanalogen och plasminogenanalogen atervinns ur odlingssubstratet, och att blodkoaguleringsenzy-met är kallikrein, faktor Xlla, XIa, IXa, Vila, Xa, trombin (faktor Ila) eller aktiverat protein C. 10
2. Förfarande enligt patentkrav 1, kännetecknat av att plasminogenanalogen in- nehaller en brytpunktssekvens a) P4-P3-Gly-Arg, i vilken P4 är en hydrofob rest och P3 en sur rest, b) P4-P3-Pro-Arg-Pl'-P2', i vilken saväl P4 som P3 är sinsemellan oberoende en hydrofob rest och säväl ΡΓ som P2' är oberoende en icke-sur rest, c) P2-Arg-Pl', i vilken den ena av restema P2 och ΡΓ är glycin och den andra vilken 15 som heist aminosyrarest och d) Gly-Pro-Arg.
3. Förfarande enligt patentkrav 1 eller 2, kännetecknat av att analogen innehäller en eller flera andra modifikationer (jämfört med en glu-plasminogen av vild typ), vilka kan vara en eller flera additioner, deletioner eller substitutioner.
4. Syntetisk eller rekombinant DNA-nukleinsyra, kännetecknad av att den kodar 20 en plasminogenanalog som kan aktiveras med ett blodkoaguleringsenzym för att er- hälla plasminaktivitet, varvid enzymet är kallikrein, faktor Xlla, XIa, IXa, Vila, Xa, trombin (faktor Ha) eller aktiverat protein C. •
5. Vektor, kännetecknad av att den innehäller en första nukleinsyra som kodar en plasminogenanalog enligt patentkrav 4 eller är associerad tili en kloningspunkt 25 som är funktionellt forbunden med en andra nukleinsyrasekvens som innehäller en stark promotor- och enhancersekvens som härletts frän mänskligt cytomegalovirus, en tredje nukleinsyrasekvens som kodar en polyadenyliseringssekvens som härletts ;; frän SV40, och en fjärde nukleinsyrasekvens som kodar ett valbart gpt-tecken som uttrycks ur SV40-promotom och som dessutom har en SV40-polyadenyliserings-30 signal vid 3’-änden av en valbar teckensekvens.
6. Cell eller cellinje, kännetecknad av att den ffamställts genom att transformera eller transfektera en cell eller cellinje med en nukleinsyra enligt patentkrav 4 eller 1' en vektor enligt patentkrav 5.
FI922610A 1989-12-07 1992-06-05 Förfarande för framställning av aktiverbara fibrinolytiska och antikombotiska plasminogenanaloga FI105202B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898927722A GB8927722D0 (en) 1989-12-07 1989-12-07 Proteins and nucleic acids
GB8927722 1989-12-07
GB9001912 1990-12-07
PCT/GB1990/001912 WO1991009118A2 (en) 1989-12-07 1990-12-07 Activatable fibrinolytic and anti-thrombotic proteins

Publications (3)

Publication Number Publication Date
FI922610A FI922610A (fi) 1992-06-05
FI922610A0 FI922610A0 (fi) 1992-06-05
FI105202B true FI105202B (sv) 2000-06-30

Family

ID=10667597

Family Applications (2)

Application Number Title Priority Date Filing Date
FI922609A FI922609A (fi) 1989-12-07 1992-06-05 Proteiner och nukleinsyror.
FI922610A FI105202B (sv) 1989-12-07 1992-06-05 Förfarande för framställning av aktiverbara fibrinolytiska och antikombotiska plasminogenanaloga

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI922609A FI922609A (fi) 1989-12-07 1992-06-05 Proteiner och nukleinsyror.

Country Status (21)

Country Link
US (2) US5637492A (sv)
EP (2) EP0504241A1 (sv)
JP (2) JPH05502374A (sv)
KR (2) KR920703818A (sv)
AT (1) ATE155812T1 (sv)
AU (3) AU644399B2 (sv)
CA (2) CA2069085C (sv)
DE (1) DE69031127T2 (sv)
DK (1) DK0502968T3 (sv)
ES (1) ES2106073T3 (sv)
FI (2) FI922609A (sv)
GB (1) GB8927722D0 (sv)
GR (1) GR3024990T3 (sv)
HU (1) HU211628A9 (sv)
IE (2) IE81046B1 (sv)
IL (2) IL96601A (sv)
NO (2) NO305562B1 (sv)
NZ (2) NZ236330A (sv)
PT (2) PT96103B (sv)
WO (2) WO1991009125A1 (sv)
ZA (2) ZA909853B (sv)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22277A1 (es) * 1990-05-23 1995-01-31 Cigb Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
GB9216558D0 (en) * 1992-08-04 1992-09-16 British Bio Technology Modified proteases
GB2286190B (en) * 1992-10-29 1996-05-01 British Biotech Pharm Thrombin activatable plasminogen derivatives
DE4323754C1 (de) * 1993-07-15 1994-12-01 Gruenenthal Gmbh Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
SG49862A1 (en) * 1993-08-04 2002-03-19 Ucp Gen Pharma Ag High molecular weight desulphatohirudin
ES2080657B1 (es) * 1993-09-27 1996-11-01 Britisch Bio Technology Limite Proteasas modificadas.
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
JP3880064B2 (ja) * 1994-04-26 2007-02-14 ザ チルドレンズ メディカル センター コーポレイション アンジオスタチンおよび血管形成の抑制におけるその使用
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
CA2262751A1 (en) * 1996-08-02 1998-02-12 Roche Diagnostics Gmbh Plasminogen activator capable of being activated by thrombin
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
PT947585E (pt) 1998-03-19 2001-11-30 Instrumentation Lab Spa Metodo in vitro melhorado, kits e reagentes para a peaquisa de defeitos de coagulacao sanguinea
WO2000010506A2 (en) 1998-08-20 2000-03-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
IN190822B (sv) * 1998-12-24 2003-08-23 Council Scient Ind Res
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
JP2004508048A (ja) * 2000-09-05 2004-03-18 カロリンスカ　イノベーションズ　アクティーエボラーグ 内皮細胞増殖阻害物質に関する材料と方法
DE10108212A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108100A1 (de) * 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
DE10108211A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) * 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
WO2007144173A1 (en) 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
WO2008054592A2 (en) * 2006-09-29 2008-05-08 Proteomtech, Inc. Methods for production of recombinant plasminogen and plasmin polypeptides
CN1970574B (zh) * 2006-12-08 2010-08-25 中国药科大学 溶栓和抗凝双重功效融合蛋白、制备方法及其应用
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
JP2012533560A (ja) 2009-07-15 2012-12-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞における取り込みが制御可能なペプチド
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
EP2600891B1 (en) * 2010-08-05 2018-01-17 Council of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
AU2012290318B2 (en) 2011-07-29 2016-09-01 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
KR20140064841A (ko) * 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. 플라스미노겐 변이체 및 플라스민 변이체
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
CA3128911C (en) 2013-01-30 2023-10-17 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1897087A (en) * 1927-12-14 1933-02-14 Tamarin Bernard Jacques Vacuum cleaner cord control device
US3608333A (en) * 1968-06-20 1971-09-28 Bison Mfg Co Inc Vacuum cleaner and power unit
US4880776A (en) * 1983-12-24 1989-11-14 Beecham Group P.L.C. Plasmin A-chain urokinase B-chain hybrid protein
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
DE3410437A1 (de) * 1984-03-22 1985-09-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von proteinen
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5200340A (en) * 1987-05-22 1993-04-06 Zymogenetics, Inc. Thrombin-activated tissue plasminogen activators
EP0292009A1 (en) * 1987-05-22 1988-11-23 Zymogenetics, Inc. Fibrinolytic proteins
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
DE3883453T2 (de) * 1987-07-01 1994-03-17 Beecham Group Plc Hybride Plasminogenaktivatoren.
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1340802C (en) * 1987-08-15 1999-10-26 Yasuyuki Takahashi Senile amyloid precursor protein and an antibody specific for the same
WO1989001513A1 (en) * 1987-08-19 1989-02-23 Sagami Chemical Research Center Fast-acting prourokinase
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
AU646633B2 (en) * 1989-02-17 1994-03-03 Codon Soluble analogs of thrombomodulin
JPH05500748A (ja) * 1989-05-01 1993-02-18 ザ　ユニバーシティ　オブ　ノートル　ダム　デュ　ラック 真核細胞系でのヒトプラスミノーゲンの発現方法および物質
US5164304A (en) * 1989-05-04 1992-11-17 Sri International Method and vectors for stabilizing hirudin and human laminin b1 expression
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus

Also Published As

Publication number Publication date
JPH05502374A (ja) 1993-04-28
AU6954091A (en) 1991-07-18
PT96103A (pt) 1991-09-30
ZA909854B (en) 1992-08-26
DE69031127T2 (de) 1998-02-05
PT96104A (pt) 1991-09-30
AU644399B2 (en) 1993-12-09
NO922238D0 (no) 1992-06-05
WO1991009118A2 (en) 1991-06-27
IL96601A0 (en) 1991-09-16
DE69031127D1 (de) 1997-09-04
CA2069105A1 (en) 1991-06-08
NZ236330A (en) 1993-05-26
GR3024990T3 (en) 1998-01-30
US5434073A (en) 1995-07-18
ATE155812T1 (de) 1997-08-15
CA2069085A1 (en) 1991-06-08
JPH05502375A (ja) 1993-04-28
WO1991009125A1 (en) 1991-06-27
AU643247B2 (en) 1993-11-11
NO922238L (no) 1992-08-06
EP0504241A1 (en) 1992-09-23
US5637492A (en) 1997-06-10
CA2069085C (en) 2000-02-01
EP0502968A1 (en) 1992-09-16
KR920703803A (ko) 1992-12-18
ES2106073T3 (es) 1997-11-01
WO1991009118A3 (en) 1991-10-31
JP2851423B2 (ja) 1999-01-27
AU6965691A (en) 1991-07-18
FI922610A (fi) 1992-06-05
PT96103B (pt) 1998-08-31
IL96601A (en) 1999-05-09
GB8927722D0 (en) 1990-02-07
NO922237L (no) 1992-08-06
IE904416A1 (en) 1991-07-17
AU4497693A (en) 1993-11-18
FI922609A0 (fi) 1992-06-05
FI922609A (fi) 1992-06-05
KR920703818A (ko) 1992-12-18
KR100188302B1 (ko) 1999-06-01
EP0502968B1 (en) 1997-07-23
NO922237D0 (no) 1992-06-05
HU211628A9 (en) 1995-12-28
ZA909853B (en) 1992-08-26
IE904417A1 (en) 1991-06-19
NZ236401A (en) 1992-03-26
FI922610A0 (fi) 1992-06-05
IL96602A0 (en) 1992-05-25
DK0502968T3 (da) 1998-03-02
NO305562B1 (no) 1999-06-21
IE81046B1 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
FI105202B (sv) Förfarande för framställning av aktiverbara fibrinolytiska och antikombotiska plasminogenanaloga
US9896676B2 (en) Compositions and methods for modulating hemostasis
FI114102B (sv) Förfarande för att framställa en plasminogenanalog som spjälks under effekten av trombin
US5688664A (en) Thrombin activatable plasminogen analogues
FI102844B (sv) Förfarande för framställning av en förbättrad terapeutiskt aktiv aktiv ator för vävnadsplasminogen
AU3064989A (en) Modified gene sequences encoding modified tpa and products therefrom
JPH06133780A (ja) 新規なｔ−ＰＡ改変体
JPH06327473A (ja) 新規なｔ−ＰＡ改変体

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: BRITISH BIOTECH PHARMACEUTICALS LIMITED